England's influential National Institute for Health and Clinical Excellence (NICE) has reversed its earlier position opposing use of drug-eluting stents (DES), clearing the way for reimbursement of such interventions in what is estimated to be a $100 million market. If there are no appeals against the draft decision, the final guidance on DES will go into effect in March.